Overcoming Clinical Challenges in BRIC Markets - China - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Overcoming Clinical Challenges in BRIC Markets - China Thomson Reuters Cortellis Competitive Intelligence

Source: Applied Clinical Trials

Read the companion parts of this report on Brazil , Russia, and India.

4E: Late-stage trials are the most prevalent in India, with top therapeutic areas mimicking the global trend: diabetes, pulmonary diseases, and rheumatoid arthritis.

5A: China is the only BRIC country seeing an increase in the amount of clinical trials they are initiating every year. And clearly, large pharma lags behind Chinese-based trial initiations in that country. Recent developments in partnerships include AstraZeneca’s with Beijing’s premier clinical research laboratory, Pharmaron. Extensive networks of on-ground expertise with CROs is growing with entities like Novartis, Quintiles, Parexel, Covance’s central laboratory, and Catalant’s recently opened clinical trial supply facility in shanghai.

5E: Phase I trials must be performed in China with Chinese patients for all new drugs not already registered in another country. Due to the high incidence of local sponsors, however, early-stage trials are relatively elevated compared to other BRIC countries. Phase III trials are being initiated in oncology and pulmonology in numbers close to those of early-stage trials, which focus mainly on oncology.

SOURCE: Thomson Reuters Cortellis Competitive Intelligence
Read the full report here.

 

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here